Open AccessEvaluation of treatment outcomes of triple-negative breast cancer
Author(s) -
Ahmet Cinkaya,
Mustafa Akın,
Adem Şengül
Publication year - 2016
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.154000
Subject(s) - breast cancer , medicine , oncology , triple negative breast cancer , progesterone receptor , cytokeratin , androgen receptor , cancer , estrogen receptor , basal (medicine) , hormone receptor , immunohistochemistry , prostate cancer , insulin
Breast cancer is the most common cancer in women. Treatment responses are variable depending on tumor morphological characteristics, clinical characteristics, and hormonal receptor levels. In current medical practice, estrogen receptor (ER), progesterone receptor (PGR), and human epidermal growth factor receptor 2 (HER2) levels have been identified as important prognostic factors; they can change prognosis and treatment modalities. In this study, the prognostic factors of patients with triple-negative breast cancer (TNBC) were examined retrospectively.